Search results for "Leishmaniasis"

showing 10 items of 148 documents

Humanized mice in cutaneous leishmaniasis—Suitability analysis of human PBMC transfer into immunodeficient mice

2019

Humanized mice represent a suitable preclinical test system for example therapeutic interventions in various disease settings, including infections. Here, we intended to establish such system for cutaneous leishmaniasis by infecting T, B and NK cell-deficient mice adoptively transferred with human peripheral blood mononuclear cells (PBMC). L major infection led to the establishment of parasite lesions harbouring viable parasites and human T cells, but parasite elimination was not seen due to a species-specific activity of T cell-derived human IFNγ. In addition, up to 50% of infected mice succumbed to severe graft-versus-host disease. In summary, even though long-term disease outcome assessm…

0301 basic medicineT cellGraft vs Host DiseaseLeishmaniasis CutaneousDermatologyDiseaseBiochemistryPeripheral blood mononuclear cellLesionInterferon-gammaMice030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSpecies SpecificityCutaneous leishmaniasisT-Lymphocyte SubsetsIn vivoAnimalsHumansMedicineParasite hostingMolecular Biologybusiness.industryMacrophagesLeishmaniasismedicine.diseaseAdoptive Transfer030104 developmental biologymedicine.anatomical_structureModels AnimalImmunologyDisease ProgressionLeukocytes MononuclearHeterograftsmedicine.symptombusinessExperimental Dermatology
researchProduct

A case of visceral leishmaniasis and pulmonary tuberculosis in a post-partum woman

2015

AbstractVisceral leishmaniasis due to Leishmania infantum is a vector-borne zoonotic disease transmitted by sand fly bites endemic in rural or periurban areas of the Mediterranean basin. Pregnancy is accompanied by changes in immune response, mainly a decrease in cellular immunity and a proportional increase in humoral immunity. These physiological events result in increased risk of infection by pathogens whose immunity is based on a T-helper 1 predominant response. We describe a case of visceral leishmaniasis and pulmonary tuberculosis diagnosed in a post-partum woman four days after delivery. The diagnosis of leishmaniasis should be considered in pregnant women with fever and haematologic…

Microbiology (medical)AdultSettore MED/07 - Microbiologia E Microbiologia ClinicaCellular immunityTuberculosisSettore MED/17 - Malattie Infettivelcsh:Infectious and parasitic diseasesYoung AdultPulmonary TuberculosisImmune systemImmunityPregnancyparasitic diseasesPulmonary TuberculosiMedicineHumanslcsh:RC109-216Leishmania infantumTuberculosis PulmonaryVisceral leishmaniasisVisceral leishmaniasibiologybusiness.industryCoinfectionPostpartum PeriodLeishmaniasisGeneral Medicinebiology.organism_classificationmedicine.diseasePregnancy ComplicationsInfectious DiseasesVisceral leishmaniasisHumoral immunityImmunologyLeishmaniasis VisceralFemaleLeishmania infantumbusinessInternational Journal of Infectious Diseases
researchProduct

Keratinocytes Determine Th1 Immunity during Early Experimental Leishmaniasis

2010

Experimental leishmaniasis is an excellent model system for analyzing Th1/Th2 differentiation. Resistance to Leishmania (L.) major depends on the development of a L. major specific Th1 response, while Th2 differentiation results in susceptibility. There is growing evidence that the microenvironment of the early affected tissue delivers the initial triggers for Th-cell differentiation. To analyze this we studied differential gene expression in infected skin of resistant and susceptible mice 16h after parasite inoculation. Employing microarray technology, bioinformatics, laser-microdissection and in-situ-hybridization we found that the epidermis was the major source of immunomodulatory mediat…

KeratinocytesCellular differentiationImmunology/Innate ImmunityInterleukin-1betaGene ExpressionInfectious Diseases/Skin InfectionsMiceT-Lymphocyte SubsetsLeishmania majorBiology (General)In Situ HybridizationOligonucleotide Array Sequence AnalysisSkinRegulation of gene expressionMice Inbred BALB CReverse Transcriptase Polymerase Chain ReactionCell DifferentiationImmunohistochemistryInterleukin-12MicrodissectionResearch ArticleQH301-705.5ImmunologyLeishmaniasis CutaneousBiologyMicrobiologyTh2 CellsImmune systemCutaneous leishmaniasisImmunology/Immunity to InfectionsVirologyGeneticsmedicineAnimalsDermatology/Skin InfectionsMolecular BiologyInterleukin 4Epidermis (botany)Interleukin-6Gene Expression ProfilingLasersTh1 CellsRC581-607medicine.diseasebiology.organism_classificationMice Inbred C57BLGene expression profilingDisease Models AnimalImmunology/Immune ResponseImmunologyOsteopontinParasitologyInterleukin-4Immunologic diseases. AllergyPLoS Pathogens
researchProduct

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner

2017

Functional impairment of T-cells and a concomitant augmented expression of programmed death-1 (PD-1) have been observed in visceral leishmaniasis patients, as well as in experimental models for visceral and cutaneous leishmaniasis. The PD-1/PD-1-ligand (PD-1/PD-L) interaction negatively regulates T-cell effector functions, which are required for parasite control during leishmaniasis. The aim of this study was to elucidate the impact of the PD-1/PD-L axis in a human primary in vitro infection model of Leishmania major (Lm). Blocking the PD-1/PD-L interaction with nivolumab increased T-cell proliferation and release of the proinflammatory cytokines TNFα and IFNγ during the cocultivation of Lm…

lcsh:Immunologic diseases. Allergyprogrammed death-1 ligand 10301 basic medicineprogrammed death-1 ligand 2ImmunologyProinflammatory cytokine03 medical and health sciencesCutaneous leishmaniasisPD-L1medicineImmunology and AllergyLeishmania majorGranulysinOriginal Researchprogrammed death-1Leishmanianivolumabhuman macrophagesbiologyT-cellsmedicine.diseasebiology.organism_classification030104 developmental biologyGranzymePerforinImmunologybiology.proteinTumor necrosis factor alphahuman dendritic cellslcsh:RC581-607Frontiers in Immunology
researchProduct

Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis

2018

Abstract: Chemotherapy is currently the only effective approach to treat all forms of leishmaniasis. However, its effectiveness is severely limited due to high toxicity, long treatment length, drug resistance, or inadequate mode of administration. As a consequence, there is a need to identify new molecular scaffolds and targets as potential therapeutics for the treatment of this disease. We report a small series of 1,2‐substituted‐1H‐benzo[d]imidazole derivatives (9ad) showing affinity in the submicromolar range (Ki = 0.150.69 μM) toward Leishmania mexicanaCPB2.8ΔCTE, one of the more promising targets for antileishmanial drug design. The compounds confirmed activity in vitro against intrace…

BenzimidazoleCell SurvivalIn silicoLeishmania mexicanaAntiprotozoal AgentsDrug Evaluation PreclinicalProtozoan ProteinsDrug resistanceCysteine Proteinase InhibitorsPharmacologyAntileishmanial agents Benzimidazole derivatives Docking studies In silico profiling Leishmania mexicanaCPB2.8 Biochemistry Molecular Medicine01 natural sciencesBiochemistryLeishmania mexicanaCell LineInhibitory Concentration 50chemistry.chemical_compoundCysteine ProteasesDrug DiscoverymedicineHumansAmastigoteLeishmaniasisBiologyEnzyme AssaysPharmacologyBinding Sitesbiology010405 organic chemistryChemistryPharmacology. TherapyOrganic ChemistryHydrogen BondingLeishmaniasisbiology.organism_classificationmedicine.diseaseLeishmaniaProtein Structure Tertiary0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryChemistryMolecular MedicineBenzimidazolesHuman medicineLeishmania infantumChemical biology and drug design
researchProduct

The Absence of HIF-1α Increases Susceptibility to Leishmania donovani Infection via Activation of BNIP3/mTOR/SREBP-1c Axis

2020

Summary: Hypoxia-inducible factor-1 alpha (HIF-1α) is considered a global regulator of cellular metabolism and innate immune cell functions. Intracellular pathogens such as Leishmania have been reported to manipulate host cell metabolism. Herein, we demonstrate that myeloid cells from myeloid-restricted HIF-1α-deficient mice and individuals with loss-of-function HIF1A gene polymorphisms are more susceptible to L. donovani infection through increased lipogenesis. Absence of HIF-1α leads to a defect in BNIP3 expression, resulting in the activation of mTOR and nuclear translocation of SREBP-1c. We observed the induction of lipogenic gene transcripts, such as FASN, and lipid accumulation in inf…

0301 basic medicineSREBP-1cHIF1A Gene[SDV]Life Sciences [q-bio]Leishmania donovaniHIF-1αGeneral Biochemistry Genetics and Molecular BiologyMitochondrial Proteins03 medical and health sciences0302 clinical medicinevisceral leishmaniasisAnimalsHumansMyeloid Cellslcsh:QH301-705.5GenelipogenesisPI3K/AKT/mTOR pathwayDisease ResistanceMice Inbred BALB CInnate immune systembiologyIntracellular parasiteLipogenesisMacrophagesTOR Serine-Threonine KinasesGenetic VariationMembrane Proteinsbiology.organism_classificationLeishmaniaHypoxia-Inducible Factor 1 alpha SubunitFASNLipidsmacrophages3. Good healthCell biologyUp-RegulationMice Inbred C57BL030104 developmental biologylcsh:Biology (General)myeloid cellsLipogenesisLeishmaniasis VisceralDisease SusceptibilityacetateSterol Regulatory Element Binding Protein 1030217 neurology & neurosurgeryLeishmania donovaniSignal Transduction
researchProduct

Treatment options for leishmaniasis.

2021

Leishmaniasis is broadly classified into three types: cutaneous, mucocutaneous and visceral. The visceral form is most dangerous and can result in death. Although leishmaniasis is an ancient disease, its treatment is still challenging. Several drugs, differing in their cost, toxicity, treatment duration and emergence of drug resistance, are used for different types of leishmaniasis. To overcome these limitations, the search for newer drugs and other treatments continues. In this article, we discuss conventional drugs, other treatments, including newer options such as immunotherapy and immunochemotherapy, and future prospects for leishmaniasis treatment.

medicine.medical_specialtyHot Temperaturemedicine.medical_treatmentTreatment durationMucocutaneous zone610 MedizinAntiprotozoal AgentsDermatologyDiseaseDrug resistance610 Medical sciencesmedicineHumansLeishmaniasisbusiness.industryTreatment optionsLeishmaniasisImmunotherapymedicine.diseaseDermatologyCombined Modality TherapyPhotochemotherapyCryotherapyDrug Therapy CombinationImmunotherapybusinessClinical and experimental dermatologyReferences
researchProduct

Focused ultrasound to diagnose HIV-associated tuberculosis (FASH) in the extremely resource-limited setting of South Sudan: a cross-sectional study

2019

ObjectiveOur cross-sectional study aimed at evaluating the diagnostic performance of Focused Assessment with Sonography for HIV-associated tuberculosis (FASH) to detect extrapulmonary tuberculosis in extremely resource-limited settings, with visceral leishmaniasis as a differential diagnosis with overlapping sonographic feature.DesignCross-sectional study.SettingVoluntary Counselling and Testing Centre (VCT) of Yirol Hospital, South Sudan.ParticipantsFrom May to November 2017, 252 HIV-positive patients out of 624 newly admitted to VCT Centre were registered for antiretroviral treatment. According to the number of trained doctors available to practise ultrasound (US) scan, a sample of 100 pa…

AdultMalemedicine.medical_specialtyTuberculosisAdolescentCross-sectional studyPoint-of-Care Systemsextra-pulmonary tuberculosisinfectious diseaseHuman immunodeficiency virus (HIV)Physical examinationHIV Infectionsmedicine.disease_causeGlobal Healthinfectious diseasesSettore MED/42 - Igiene Generale E Applicata03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineHumansTuberculosisfash030212 general & internal medicine1506PathologicalUltrasonographymedicine.diagnostic_testbusiness.industryultrasoundResearchextra-pulmonary tuberculosi1699General MedicineMiddle Agedmedicine.diseaseCD4 Lymphocyte CountVisceral leishmaniasisCross-Sectional StudiesEffusionFemaleDifferential diagnosissouth sudanbusiness030217 neurology & neurosurgery
researchProduct

Oral leishmaniasis in an HIV-infected patient.

2000

As in most countries in the Mediterranean basin, leishmaniasis is endemic in Italy, where it has visceral (VL) and cutaneous (CL) forms caused by viscerotropic and dermotropic strains of Leishmania infantum, respectively. With the spread of the acquired immunodeficiency syndrome (AIDS) epidemic, the number of coinfections with Leishmania and human immunodeficiency virus (HIV) is increasing. Between 35% and 50% of the adult VL cases diagnosed annually in Sicily from 1991 to 1995 were related to HIV [1]; although cases of coinfection have been reported in 28 countries worldwide, the majority of these cases (1440 from 1990 to 1998) have been notified in four countries (Spain, Italy, France, Po…

Microbiology (medical)AdultLeishmaniasis MucocutaneousMaleHIV InfectionsAcquired immunodeficiency syndrome (AIDS)medicineHumansSidaLeishmaniasisbiologyLamivudineLeishmaniasisGeneral MedicineMiddle Agedmedicine.diseasebiology.organism_classificationLeishmaniaVirologyInfectious DiseasesImmunologyCoinfectionFemaleViral diseaseLeishmania infantumMouth Diseasesmedicine.drugEuropean journal of clinical microbiologyinfectious diseases : official publication of the European Society of Clinical Microbiology
researchProduct

Answer to “Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas”

2017

Leiomyosarcoma0301 basic medicineLeiomyosarcomaPathologymedicine.medical_specialtySkin Neoplasmsbusiness.industryLeishmaniasis CutaneousGeneral Medicinemedicine.diseasePathology and Forensic Medicine03 medical and health sciences030104 developmental biology0302 clinical medicineRecurrence030220 oncology & carcinogenesismedicineHumansTumor Suppressor Protein p53businessAnnals of Diagnostic Pathology
researchProduct